Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis Sa (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 120,321,744
  • Shares Outstanding, K 2,543,800
  • Annual Sales, $ 38,408 M
  • Annual Income, $ 4,864 M
  • 36-Month Beta 1.00
  • Price/Sales 3.19
  • Price/Cash Flow 10.16
  • Price/Book 1.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.97 +7.57%
on 04/21/17
47.52 -0.46%
on 04/28/17
+1.95 (+4.30%)
since 03/28/17
3-Month
39.71 +19.11%
on 01/30/17
47.52 -0.46%
on 04/28/17
+7.42 (+18.61%)
since 01/27/17
52-Week
36.81 +28.50%
on 10/26/16
47.52 -0.46%
on 04/28/17
+4.45 (+10.39%)
since 04/28/16

Most Recent Stories

More News
Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

BAYRY : 124.4280 (+1.48%)
GILD : 68.55 (-0.04%)
REGN : 388.49 (+5.97%)
SNY : 47.30 (+0.83%)
Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

HSKA : 108.25 (+2.88%)
REGN : 388.49 (+5.97%)
AMGN : 163.32 (+0.37%)
SNY : 47.30 (+0.83%)
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate...

CNCE : 15.87 (-0.75%)
VRTX : 118.30 (+0.75%)
PFE : 33.92 (+0.18%)
SNY : 47.30 (+0.83%)
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

MRK : 62.33 (-0.40%)
LLY : 82.06 (+0.90%)
NVS : 77.03 (-0.04%)
PFE : 33.92 (+0.18%)
GSK : 40.90 (+0.29%)
SNY : 47.30 (+0.83%)
BMY : 56.05 (+0.68%)
Sanofi Delivers Robust Q1 2017 Financial Results

Sanofi (NYSE: SNY; EURONEXT: SAN)

SNY : 47.30 (+0.83%)
Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for Kevzara (sarilumab)...

SAN : 6.52 (+1.09%)
REGN : 388.49 (+5.97%)
SNY : 47.30 (+0.83%)
Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

NVS : 77.03 (-0.04%)
REGN : 388.49 (+5.97%)
AMGN : 163.32 (+0.37%)
SNY : 47.30 (+0.83%)
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

LLY : 82.06 (+0.90%)
INCY : 124.28 (+0.09%)
SNY : 47.30 (+0.83%)
BIIB : 271.21 (-1.94%)
New Data Suggest Positive Effects of Sanofi Genzyme's Aubagio(R) (teriflunomide) on Cortical Gray Matter Atrophy

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio(R) (teriflunomide) on cortical gray...

SNY : 47.30 (+0.83%)
New Investigational Data on Six-Year Efficacy of Sanofi Genzyme's Lemtrada(R) (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today positive new six-year investigational data from a post-hoc analysis of the extension study of Lemtrada(R)...

SNY : 47.30 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Support & Resistance

2nd Resistance Point 47.86
1st Resistance Point 47.58
Last Price 47.30
1st Support Level 46.96
2nd Support Level 46.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.